CA-125

Aspira Women’s Health Initiates Prospective Clinical Study for Benign Risk Monitoring and High Risk Early Ovarian Cancer Detection with Northwell Health®

Retrieved on: 
Wednesday, May 12, 2021
Gynaecology, Anatomy, Branches of biology, Medical specialties, Ovarian cancer, Adnexal mass, Endometriosis, Ovary, CA-125

Northwell Health treats over 2 million patients annually and employs over 16,000 credentialled physicians.\nThe study will enroll over 600 prospective women with adnexal masses.

Key Points: 
  • Northwell Health treats over 2 million patients annually and employs over 16,000 credentialled physicians.\nThe study will enroll over 600 prospective women with adnexal masses.
  • Ovarian cancer risk will be assessed by both CA125 and Aspira\xe2\x80\x99s OVASight proprietary algorithm.
  • The secondary endpoint is to test additional genomic markers to develop a proteogenomic test for early-stage detection of ovarian cancer.
  • Aspira Women\xe2\x80\x99s Health is particularly focused on closing the ethnic disparity gap in ovarian cancer risk assessment and developing solutions for pelvic diseases such as pelvic mass risk assessment and endometriosis.

Aspira Women’s Health Recognizes the Importance of Bridging the Gap in Ovarian Cancer Risk Assessment Disparities During Black History Month

Retrieved on: 
Wednesday, February 17, 2021
Gynaecology, Medical specialties, Gynaecological cancer, Cancer, Oncology, Ovarian cancer, CA-125, Clinical medicine

This month, Aspira Womens Health Inc. (Nasdaq: AWH), a bioanalytical-based womens health company, is underscoring its commitment to addressing racial and ethnic disparities in ovarian cancer risk assessment.

Key Points: 
  • This month, Aspira Womens Health Inc. (Nasdaq: AWH), a bioanalytical-based womens health company, is underscoring its commitment to addressing racial and ethnic disparities in ovarian cancer risk assessment.
  • OVA1plus improves the detection of ovarian cancer risk in Black women because of its superior sensitivity and its multi-biomarker algorithm which measures changes in nutrition and inflammation which are not ethnicity specific.
  • Addressing the current ethnic disparities in ovarian cancer assessment is a critical part of our companys mission, states Valerie Palmieri, President and CEO, of Aspira Womens Health.
  • Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association analysis in the Ovarian Cancer Association Consortium.

Tmunity Announces First Patient Dosed in Phase 1 Clinical Trial with CART-TnMUC1

Retrieved on: 
Wednesday, January 15, 2020
Research, Technology, FDA, Other Technology, Clinical trials, Biotechnology, Pharmaceutical, Health, Science, Oncology, MUC1, Branches of biology, Mucin, Biology, Pankomab, CA-125, the CART-TnMUC1-01 Phase 1 Trial, Tmunity Therapeutics

The MUC1 glycoprotein is a transmembrane epithelial mucin normally expressed on the apical surface of most simple glandular epithelial cells.

Key Points: 
  • The MUC1 glycoprotein is a transmembrane epithelial mucin normally expressed on the apical surface of most simple glandular epithelial cells.
  • In tumors that arise from these cells, an alternate form of MUC1 is frequently overexpressed on the cancer cell surface.
  • This clinical trial marks the third program from our portfolio to enter the clinical testing phase since our company was founded in 2015.
  • The primary objective of the trial is to establish safety and the recommended Phase 2 dose of CART-TnMUC1 that can be administered with lymphodepletion.

Clovis Oncology Announces Rubraca®▼ (rucaparib) Now Available for Women with Relapsed Ovarian Cancer in England Through the Cancer Drugs Fund

Retrieved on: 
Friday, October 11, 2019
Biotechnology, Pharmaceutical, Oncology, Health, Genetics, Clinical trials, RTT, Oncology, Gynaecological cancer, Cancer, Medical specialties, Health, Gynaecology, Ovarian cancer, Treatment of cancer, Ovarian disease, CA-125, Rubraca® (rucaparib), Clovis Oncology

Many women with relapsed ovarian cancer know that they are facing a future of managing their disease as a chronic illness.

Key Points: 
  • Many women with relapsed ovarian cancer know that they are facing a future of managing their disease as a chronic illness.
  • For too long ovarian cancer treatment options beyond chemotherapy or surgery have been limited, and todays announcement means that women with ovarian cancer have more choice in their treatment than ever before, said Annwen Jones, Chief Executive of Target Ovarian Cancer, a United Kingdom ovarian cancer charity.
  • Target Ovarian Cancer has long campaigned for better treatment for women with ovarian cancer and we are delighted to see this latest development.
  • This represents a significant step in the effective management of relapsed ovarian cancer in the NHS in England.

Vermillion Announces Two Independent Publications Showing OVA1® (MIA- Multivariate Index Assay) Demonstrates Improved Ovarian Malignancy Risk Detection in African-American Women

Retrieved on: 
Wednesday, September 4, 2019
General Health, Pharmaceutical, Oncology, African-American, Consumer, Women, Biotechnology, FDA, Health, Medical specialties, CA-125, RTT, Oncology, Medicine, Ovarian cancer, Health

In addition, even applying a more conservative 2007 cutoff for premenopausal women (CA125 >67 U/ml, Dearking 2007)4, OVA1 still outperformed CA125 whose sensitivity was only 62.5%.

Key Points: 
  • In addition, even applying a more conservative 2007 cutoff for premenopausal women (CA125 >67 U/ml, Dearking 2007)4, OVA1 still outperformed CA125 whose sensitivity was only 62.5%.
  • It is so critically important to investigate the sensitivity of such detection methods based on the inherent differences in individual populations.
  • OVA1 proactively assesses the risk of ovarian malignancy from a simple blood test, as a pre-operative biopsy is not medically appropriate.
  • In March 2016, Vermillion received FDA clearance for Overa, a Multivariate Index Assay 2nd Generation (MIA2G) test with significantly improved specificity and ease of use.

Vermillion Announces Publication of New Study Demonstrating Overa’s Greater Sensitivity in Detecting Ovarian Cancer Compared with ROMA, HE4 + CA125, and CA125 Alone

Retrieved on: 
Tuesday, July 16, 2019
Publishing, Health, Women, Oncology, Communications, Research, Science, Consumer, Gynaecology, Medical specialties, Medicine, Health, RTT, Adnexal mass, CA-125, Ovarian cancer, Obstetrics and gynaecology

These findings advance our ability to detect ovarian malignancy and provide clinicians with reliable tools to screen adnexal masses.

Key Points: 
  • These findings advance our ability to detect ovarian malignancy and provide clinicians with reliable tools to screen adnexal masses.
  • said Lee Shulman, M.D., principal investigator and Anna Lapham Professor of Obstetrics and Gynecology, Feinberg School of Medicine, Northwestern University.
  • Overa sensitivity also tended to outperform ROMA (76.2%; 95%CI, 66.1% - 84.0%) in detection of combined early stage (I and II) cancer.
  • As compared to CA125 and ROMA, Overa exhibited the highest sensitivity according to menopausal status.

Quest PharmaTech Signs License Agreement with OncoCare Therapeutics to Develop and Commercialize Targeted Cancer Therapy Technology in the U.S.

Retrieved on: 
Wednesday, November 28, 2018
Medicine, Biotechnology, Health, Biology, CA-125, Targeted therapy, Biopharmaceutical, Monoclonal antibody

In return for granting the license rights to the U.S., Quest will receive a 45% ownership interest in OncoCare Therapeutics, whose management includes Dr. Michael A.

Key Points: 
  • In return for granting the license rights to the U.S., Quest will receive a 45% ownership interest in OncoCare Therapeutics, whose management includes Dr. Michael A.
  • "OncoCare Therapeutics is committed to pursuing the research and development and applying the clinical efforts needed to bring these new pancreatic cancer drug candidates to market.
  • Quest PharmaTech Inc is a publicly traded, Canadian based biopharmaceutical company developing products to improve the quality of life.
  • Quest, through its ownership interest in OncoCare Therapeutics, is developing an antibody licensed from University of Nebraska Medical Center, AR 9.6 mAb against truncated O-glycan on MUC16, for targeted cancer therapy applications.